dihexa patent | 1401708-83-5 | BGC70883 Synapse (Dihexa) Cognitive Peptide Therapy

Smith I, Hyland K, Kendall B

Angelman Syndrome: Ube3a Loss of expression of the ubiquitin-protein ligase E3a (UBE3A) is associated with most cases of Angelman syndrome, which is a rare syndrome of developmental delay, ID and ASD (Buiting et al., 2018), which points to a highly regulated role of UBE3A in the organism

Each component within GLOW undergoes analytical verification, including: High-Performance Liquid Chromatography (HPLC) purity analysis Identity confirmation testing Batch-level traceability documentation Controlled manufacturing standards Sterile lyophilized vial packaging Certificates of Analysis are available upon request for documentation transparency

Signaling pathway enrichment was then performed based on the Reactome pathway data 42 (access date: 2021/01) using the fisher exact test